A most valuable event organized by SOLACI and the Bolivian Society of Cardiology (SOBOCAR) for all Latin American interventional cardiologists is almost upon us. The Bolivia Sessions will be held in Cochabamba, Bolivia, on August 23rd and 24th, 2019. This event will feature over 20 Latin American special guests and modules on: Acute coronary syndrome.<a href="https://solaci.org/en/2019/07/18/2019-bolivia-sessions-discover-the-scientific-program/" title="Read more" >...</a>
1- What to Do with Blood Pressure Levels Between 130/80 and 139/89 mmHg The decision to be made with a treatment-free patient with systolic blood pressure over 160 mmHg or diastolic blood pressure over 100 mmHg is an easy one. All guidelines agree: treatment should be started immediately alongside lifestyle changes. Read also HERE 2- Low-Risk<a href="https://solaci.org/en/2019/07/02/the-most-read-articles-in-interventional-cardiology-in-solaci/" title="Read more" >...</a>
1- Surprising EXCEL Outcomes in Diabetics with Main Left Stenosis This study especially designed to compare PCI vs. CABG in patients with left main coronary artery disease and low to intermediate Syntax score showed that 30-day and 3 -year outcomes of PCI with everolimus eluting stents vs CABG were consistent both in diabetic and non-diabetic<a href="https://solaci.org/en/2019/06/06/the-most-read-articles-of-may-in-interventional-cardiology/" title="Read more" >...</a>
This new meta-analysis combines all randomized transcatheter aortic valve replacement (TAVR) vs. surgical aortic valve replacement trials and expands the scope of TAVR. Evidence across the range of risk studied supports a paradigm shift in patients with symptomatic severe aortic stenosis. The clinical superiority of TAVR compared with surgery has been demonstrated across the spectrum<a href="https://solaci.org/en/2019/05/30/europcr-2019-most-recent-tavr-meta-analysis-the-spectrum-of-treatment-reaches-all-patients/" title="Read more" >...</a>
This angiographic substudy supports the safety of drug-coated balloons in small vessels. Despite better angiographic outcomes, there were eight cases of stent thrombosis among drug-eluting stent (DES) patients, while there was none with drug-coated balloons. In patients with small vessels, using a drug-coated balloon appears safe and comparable to DES, with favorable angiographic outcomes at<a href="https://solaci.org/en/2019/05/27/europcr-2019-basket-small-2-drug-coated-balloons-vs-des-in-small-vessels/" title="Read more" >...</a>
Cost and time are the two main enemies of intravascular imaging, but lack of expertise may also play a role. A new European Association of Percutaneous Cardiovascular Interventions (EAPCI) expert consensus statement released at EuroPCR 2019 argues that there is a need for more use of intracoronary imaging in settings of acute coronary syndromes and<a href="https://solaci.org/en/2019/05/27/europcr-2019-intravascular-imaging-almost-indispensable-for-planning-an-angioplasty/" title="Read more" >...</a>
Patients with atrial fibrillation (AF) unsuitable for anticoagulation because of bleeding risk, require other strategies to prevent stroke. For some years, there have been in the market (limited to some places; not as part of the regular agenda of cardiologists and hematologists) devices to occlude the atrium that have been proved safe and effective. These<a href="https://solaci.org/en/2019/05/19/new-percutaneous-devices-to-prevent-embolism-in-atrial-fibrillation/" title="Read more" >...</a>
Eighty years did the trick for one the countries with more experience in transcatheter aortic valve replacement (TAVR), which made it the new “standard of care” to treat elderly patients. Following in the footsteps of pioneer Alain Cribier, Germany has led the adoption of TAVR in Europe and the rest of the world. Since 2008,<a href="https://solaci.org/en/2019/03/26/after-100000-patients-tavr-becomes-the-new-standard-of-care/" title="Read more" >...</a>
iFR is a safe alternative for lesion deferral even when it comes to the left anterior descending artery (LAD). What is more, patients deferred with iFR showed significantly fewer events than patients deferred using FFR. Neither clinical cardiologists nor interventionists feel comfortable deferring LAD treatment, because it is often perceived as high risk. If functional<a href="https://solaci.org/en/2019/02/07/clinical-events-after-deferral-of-lad-treatment-guided-by-ffr-or-ifr/" title="Read more" >...</a>
1- What’s New in the European Guidelines on Peripheral Arterial Disease Since the last version of the European guidelines on the diagnosis and treatment of peripheral arterial disease in 2011, there have been many trials and registries that warrant guideline adjustments in many aspects. The first novelty is the teamwork that gave way to these<a href="https://solaci.org/en/2019/02/04/the-most-relevant-articles-of-2018-in-peripheral-vascular-disease/" title="Read more" >...</a>